Eli Lilly Slashes Prices On Blockbuster Weight-Loss Drug Zepbound With New Single-Dose Vials, Retail Optimism Climbs

$Eli Lilly and Co (LLY.US)$ has introduced single-dose vials of its weight-loss drug Zepbound (tirzepatide) to improve access for adults with obesity. The 2.5 mg and 5 mg single-dose vials are priced at a 50% or greater discount compared to other GLP-1 medicines for obesity, making it more affordable for patients.

The 5 mg maintenance dose showed significant effectiveness in clinical studies, helping patients achieve an average of 15% weight loss after 72 weeks. A four-week supply of the 2.5 mg vial costs $399, while the 5 mg dose is priced at $549.

Following this announcement, retail sentiment on Stocktwits improved to ‘neutral’ from a previously bearish outlook. This comes after Eli Lilly reported strong Q2 results, with earnings per share of $3.92 beating estimates of $2.60 and revenue of $11.30 billion exceeding expectations. The company also raised its full-year guidance by $3 billion, driven by the success of Mounjaro and Zepbound.